Riwaa Frequency Headache Relief Device Treatment
A non-invasive nerve stimulation device targeting the great occipital nerve with mechanical vibrations addresses the limitations of traditional migraine treatments, providing a safe and effective alternative for reducing migraine symptoms.
Patent Information
- Application Number
- SA1020263161
- Authority / Receiving Office
- SA · SA
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-04-15
- Publication Date
- 2026-10-05
AI Technical Summary
Traditional treatments for migraines, such as medication and surgery, are often ineffective for some patients and carry potential side effects, necessitating a safer and more sustainable alternative.
A non-pharmaceutical and non-surgical device that stimulates the great occipital nerve behind the ear using mechanical vibrations within a 40-100 Hz frequency range, controlled by a Seeed XIAO nRF52840 microcontroller, with features like Bluetooth connectivity, customizable vibration intensity, and safety features to ensure user comfort and device stability.
The device effectively reduces migraine intensity and frequency by precisely targeting nerve signals, offering a safe and user-friendly treatment option with potential to reduce medication dependence.
Abstract
Description
This project aims to design and develop an innovative medical device based on frequency neurostimulation technology as a non-pharmaceutical and non-surgical solution for alleviating migraine symptoms. The project idea stems from the challenges associated with traditional treatments, such as their limited effectiveness for some patients and potential side effects, thus driving the search for safer and more sustainable treatment alternatives. The device works by stimulating the great occipital nerve, located behind the ear, through precisely targeted mechanical vibrations. This technology is used to influence nerve signals associated with pain, thereby reducing the intensity and frequency of migraine attacks. The device operates within a frequency range of 40 to 100 Hz, a range chosen for its suitability for nerve stimulation without causing discomfort to the user. The system consists of a main control unit based on a Seeed XIAO nRF52840 microcontroller, which is based on the Nordic nRF52840 chip. This microcontroller handles the calculations and generates control signals in real time. Pulse width modulation (PWM) technology is used to control the vibration intensity, allowing the stimulation level to be customized to different user needs. The device incorporates an electronic circuit to drive the vibration motor, utilizing a 2N2222 NPN transistor as an electronic switch to control the motor's on / off operation, along with a 1N4007 protection diode to safeguard the circuit from reverse voltages resulting from repeated operation. This design ensures stable performance and long-term operational reliability. In terms of connectivity, the device supports Bluetooth Low Energy (BLE 5.4) using the GATT protocol, enabling wireless communication with a user interface built on the Web Bluetooth API. Through this interface, users can easily adjust device settings such as frequency, vibration intensity, and session duration, providing a flexible and interactive user experience. The device operates using a 3.7V, 500mAh lithium-polymer battery, equipped with a power management system that ensures stable and safe operation, providing up to approximately 4.7 hours of runtime. It also features several safety features, such as automatic shut-off after 30 minutes of use to prevent overstimulation, a soft start / stop function for enhanced user comfort, and the ability to monitor battery level during operation. From a design perspective, the device's C-shaped structure was developed to fit the area behind the ear, ensuring stability during use and precise targeting of vibrations to the intended nerve. A prototype of the device was manufactured, demonstrating the technical feasibility of the concept. Despite the success of the prototype, the project is still in the research and development phase and requires further clinical studies and trials to accurately assess its medical efficacy and determine its impact on migraine patients. Overall, this project represents a significant step towards providing an innovative, safe, and user-friendly treatment solution that can contribute to reducing medication dependence and improving patients' quality of life.
